Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

L-asparaginase (L-ASNase) is an enzyme that shows targeted activity against Acute Lymphoblastic Leukemia (ALL) and similar lymphoid neoplasms by facilitating the breakdown of asparagine into L-aspartic acid, thereby reducing L-asparagine levels in leukemic cells. However, its therapeutic potential is hindered by its associated toxicity, leading to complications, such as thrombosis, hemorrhage, thrombocytopenia, fibrinolysis, hypersensitivity reactions, and the development of Posterior Reversible Encephalopathy Syndrome (PRES). This review compiles documented cases of PRES linked to treating B and T cell acute lymphoblastic leukaemia in children using L-ASNase. Although this pathology is rare, understanding its management is crucial within ASNase-based chemotherapy protocols. As PRES lacks a specific treatment, focusing on symptomatic management becomes pivotal. Therefore, comprehending the underlying causes during L-ASNase treatment for acute lymphoblastic leukemia is essential. Understanding the etiology and clinical symptoms of this illness is critical for early diagnosis and treatment.

The cases of PRES described in this review include instances in which this syndrome has appeared after the administration of L-ASNase in children. In some cases, PRES developed during induction therapy, while in others, it occurred during the reinduction phase. These cases resolved days after discontinuation of L-ASNase. The findings suggest a close relationship between drug administration and the appearance of brain lesions, as evidenced by the disappearance or decrease of these lesions when the drug was eliminated from the bloodstream.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863290290240710161133
2024-07-23
2025-09-02

  • From This Site

    /content/journals/cds/10.2174/0115748863290290240710161133
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GhaliM.G.Z. StylerM.J. Etiologies, cerebral vasomotion, and endothelial dysfunction in the pathophysiology of posterior reversible encephalopathy syndrome in pediatric patients.J. Pediatr. Neurol.202018205507810.1055/s‑0040‑1702934
     [Google Scholar]
  2. Abdul wahidS. Mohd ZakiF. TumianN.R. WongC. Posterior reversible encephalopathy syndrome as the initial presentation of acute lymphoblastic leukaemia.J. Hematol. Malig.201111495610.5430/jhm.v1n1p49
     [Google Scholar]
  3. PirolaJ.P. BaenasD.F. Haye SalinasM.J. BenzaquénN.R. ColazoM. BorghiM.V. LuceroC. ÁlvarezA.C. RetamozoS. AlvarellosA. SauritV. CaeiroF. Síndrome de leucoencefalopatía posterior reversible: serie de casos y revisión de la literatura.Reumatol. Clin.202016216917310.1016/j.reuma.2018.04.00629859809
     [Google Scholar]
  4. TangJ.H. TianJ.M. ShengM. HuS.Y. LiY. ZhangL.Y. GuQ. WangQ. Study of posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia after induction chemotherapy.J. Child Neurol.201631327928410.1177/088307381558975826060305
     [Google Scholar]
  5. CecconelloD.K. MagalhãesM.R. WerlangI.C.R. LeeM.L.M. MichalowskiM.B. DaudtL.E. Asparaginase: An old drug with new questions.Hematol. Transfus. Cell Ther.202042327528210.1016/j.htct.2019.07.01031801703
     [Google Scholar]
  6. StavroulaA. MatsA. MastH. ChenW. RittaN. SirjeM. GodaE. IngaM. IdaH. KjeldS. OlafurG. AlsN. JoannaB. ArjaH. SaariS. Posterior reversible encephalopathy syndrome and other severe central nervous system adverse events in the nopho all2008 protocol: clinical and radiological findings, genetic risk factors, and prognosis.Pediatr. Blood Cancer20222022e27594
     [Google Scholar]
  7. ThavamaniA. UmapathiK.K. PuliyelM. SuperD. AllareddyV. GhoriA. Epidemiology, comorbidities, and outcomes of posterior reversible encephalopathy syndrome in children in the United States.Pediatr. Neurol.2020103212610.1016/j.pediatrneurol.2019.07.00731481327
     [Google Scholar]
  8. BorovacJ.A. BožićJ. ŽajaN. KolićK. HrbokaV. A global amnesia associated with the specific variant of posterior reversible encephalopathy syndrome (PRES) that developed due to severe preeclampsia and malignant hypertension.Oxf. Med. Case Rep.201620164768010.1093/omcr/omw01627099774
     [Google Scholar]
  9. EverettC.M. TurnerB. LoboM. Posterior reversible encephalopathy syndrome in (low renin) essential hypertension.J. R. Soc. Med.20071001152252310.1177/01410768071000111518048710
     [Google Scholar]
  10. ArslanH. YavuzA. ArslanA. AycanA. Posterior reversible encephalopathy syndrome in IgA vasculitis: Neuroimaging of a 14-year-old child.Neurol. Neurochir. Pol.201852110711110.1016/j.pjnns.2017.11.00629162292
     [Google Scholar]
  11. Tosta PérezM. Herrera BelénL. LetelierP. CalleY. PessoaA. FaríasJ.G. l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: A comprehensive review.Med. Oncol.202340515010.1007/s12032‑023‑02014‑937060469
     [Google Scholar]
  12. Vademecum Academico de MedicamentosMcGraw-Hill: Interamericana Editores, S.A2013
     [Google Scholar]
  13. ZeidanA. WangE.S. WetzlerM. Pegasparaginase : where do we stand.Expert Opin Biol Ther200991111119
     [Google Scholar]
  14. KumarK. KaurJ. WaliaS. PathakT. AggarwalD. l-asparaginase: An effective agent in the treatment of acute lymphoblastic leukemia.Leuk. Lymphoma201455225626210.3109/10428194.2013.80322423662993
     [Google Scholar]
  15. RathiB. AzadR.K. VasudhaN. HissariaP. SawlaniV. GuptaR.K. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.Pediatr. Neurosurg.200237420320510.1159/00006539512372914
     [Google Scholar]
  16. HenriksenL.T. NerstingJ. RajaR.A. FrandsenT.L. RosthøjS. SchrøderH. AlbertsenB.K. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.Br. J. Haematol.2014166221322010.1111/bjh.1286524702187
     [Google Scholar]
  17. HindujaA. Posterior reversible encephalopathy syndrome: Clinical features and outcome.Front. Neurol.2020117110.3389/fneur.2020.0007132117030
     [Google Scholar]
  18. AkinsP.T. AxelrodY. SilverthornJ.W. GuppyK. BanerjeeA. HawkM.W. Management and outcomes of malignant posterior reversible encephalopathy syndrome.Clin. Neurol. Neurosurg.2014125525710.1016/j.clineuro.2014.06.03425086431
     [Google Scholar]
  19. AndoY. OnoY. SanoA. FujitaN. OnoS. Posterior reversible encephalopathy syndrome: A review of the literature.Intern. Med.202261213514110.2169/internalmedicine.7520‑2134275982
     [Google Scholar]
  20. PanosyanE.H. GrigoryanR.S. AvramisI.A. SeibelN.L. GaynonP.S. SiegelS.E. FingertH.J. AvramisV.I. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).Anticancer Res.2004242C1121112515154634
     [Google Scholar]
  21. AlbrechtJ. Sidoryk-WęgrzynowiczM. ZielińskaM. AschnerM. Roles of glutamine in neurotransmission.Neuron Glia Biol.20106426327610.1017/S1740925X1100009322018046
     [Google Scholar]
  22. SchwartzM.K. LashE.D. OettgenH.F. TomaoF.A. L-asparaginase activity in plasma and other biological fluids.Cancer197025224425210.1002/1097‑0142(197002)25:2<244::AID‑CNCR2820250203>3.0.CO;2‑V4905152
     [Google Scholar]
  23. RiccardiR. HolcenbergJ.S. GlaubigerD.L. WoodJ.H. PoplackD.G. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.Cancer Res.19814111 Pt 1455445586895481
     [Google Scholar]
  24. PanettaJ.C. GajjarA. HijiyaN. HakL.J. ChengC. LiuW. PuiC.H. RellingM.V. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.Clin. Pharmacol. Ther.200986665165810.1038/clpt.2009.16219741605
     [Google Scholar]
  25. AyH. BuonannoF.S. SchaeferP.W. LeD.A. WangB. GonzalezR.G. KoroshetzW.J. Posterior leukoencephalopathy without severe hypertension.Neurology19985151369137610.1212/WNL.51.5.13699818862
     [Google Scholar]
  26. BartynskiW.S. BoardmanJ.F. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome.AJNR Am. J. Neuroradiol.20072871320132710.3174/ajnr.A054917698535
     [Google Scholar]
  27. LeeV.H. WijdicksE.F.M. MannoE.M. RabinsteinA.A. Clinical spectrum of reversible posterior leukoencephalopathy syndrome.Arch. Neurol.200865220521010.1001/archneurol.2007.4618268188
     [Google Scholar]
  28. SchmiegelowK. AttarbaschiA. BarzilaiS. EscherichG. FrandsenT.L. HalseyC. HoughR. JehaS. KatoM. LiangD.C. MikkelsenT.S. MörickeA. NiinimäkiR. PietteC. PuttiM.C. RaetzE. SilvermanL.B. SkinnerR. TuckuvieneR. van der SluisI. ZapotockaE. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus.Lancet Oncol.2016176e231e23910.1016/S1470‑2045(16)30035‑327299279
     [Google Scholar]
  29. StottV.L. HurrellM.A. AndersonT.J. Reversible posterior leukoencephalopathy syndrome: A misnomer reviewed.Intern. Med. J.2005352839010.1111/j.1445‑5994.2004.00750.x15705136
     [Google Scholar]
  30. Moscardó GuillemeC. Fernández DelgadoR. Sevilla NavarroJ. Astigarraga AguirreI. Rives SolàS. Sánchez de Toledo CodinaJ. Update on L-asparaginase treatment in paediatrics.An Pediatr201379532910.1016/j.anpedi.2013.03.015
     [Google Scholar]
  31. BartynskiW.S. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.AJNR Am. J. Neuroradiol.20082961043104910.3174/ajnr.A092918403560
     [Google Scholar]
  32. SharmaM. KupfermanJ.C. BrosgolY. PaternoK. GoodmanS. ProhovnikI. KirkhamF.J. PavlakisS.G. The effects of hypertension on the paediatric brain: A justifiable concern.Lancet Neurol.20109993394010.1016/S1474‑4422(10)70167‑820675195
     [Google Scholar]
  33. KieslichM. PortoL. LanfermannH. JacobiG. SchwabeD. BöhlesH. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia.J. Pediatr. Hematol. Oncol.200325648448710.1097/00043426‑200306000‑0001112794528
     [Google Scholar]
  34. BartynskiW.S. BoardmanJ.F. ZeiglerZ.R. ShadduckR.K. ListerJ. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.AJNR Am. J. Neuroradiol.200627102179219010.22141/2224‑0586.16.2.2020.20315117110690
     [Google Scholar]
  35. López GarcíaF. Amorós-MartínezA.P.S. Reversible posterior leukoencephalopathy syndrome.Neurologia200438261266
     [Google Scholar]
  36. LimanT.G. SiebertE. EndresM. Posterior reversible encephalopathy syndrome.Curr. Opin. Neurol.2019321253510.1097/WCO.000000000000064030531559
     [Google Scholar]
  37. Titos ArcosJ.C. León VillarJ. Amigo LozanoM.L. Muiña JuárezB. Reversible posterior leukoencephalopathy syndrome induced by L-asparaginase in an adolescent diagnosed with acute lymphoblastic leukemia.Rev. Neurol.2011521586010.33588/rn.5201.201042021246495
     [Google Scholar]
  38. García MartínG. Serrano CastroV. García CarrascoE. Romero AcebalM. Posterior reversible leukoencephalopathy: should location be a defining factor?Neurologia200722212212517323240
     [Google Scholar]
  39. BelaramaniK.M. LaiV. LiC.H. LeeA.C. KwongN.S. Reversible posterior leukoencephalopathy syndrome in Chinese children induced by chemotherapy: A review of five cases.Hong Kong Med. J.2011171616621282828
     [Google Scholar]
  40. HouraniR. AbboudM. HouraniM. KhalifehH. MuwakkitS. L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.Neuropediatrics2008391465010.1055/s‑2008‑107674018504683
     [Google Scholar]
  41. XiaoX. ChuS.J. TangJ.H. ZhangL.Y. ZhangB.B. Leukoencephalopathy in children with acute lymphoblastic leukemia after chemotherapy: A retrospective monocenter study.Transl. Cancer Res.202312234035010.21037/tcr‑22‑218036915585
     [Google Scholar]
  42. DanhoferP. TomečkováM. ČernáD. ZapletalováD. HorákO. AulickáŠ. JuříkováL. DomanskýJ. KovalčíkováP. PavlíkT. ŠtěrbaJ. OšlejškováH. Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study.Seizure20197211010.1016/j.seizure.2019.08.00731521834
     [Google Scholar]
  43. MusiołK. WazS. BorońM. KwiatekM. Machnikowska-SokołowskaM. GruszczyńskaK. Sobol-MilejskaG. PRES in the course of hemato-oncological treatment in children.Childs Nerv. Syst.201834469169910.1007/s00381‑017‑3664‑y29198072
     [Google Scholar]
  44. Nowak-GöttlU. KunN. WolffJ.E.A. BoosJ. KehrelB. RathB. JürgensH. Inhibition of hypercoagulation by antithrombin substitution in E. coli L‐asparaginase‐treated children.Eur. J. Haematol.1996561-2353810.1111/j.1600‑0609.1996.tb00290.x8599991
     [Google Scholar]
  45. LarsonR.A. FretzinM.H. DodgeR.K. SchifferC.A. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.Leukemia199812566066510.1038/sj.leu.24010079593262
     [Google Scholar]
  46. FleischhackG. SolymosiL. ReiterA. Bender-GötzeC. EberlW. BodeU. Imaging techniques in the diagnosis of cerebrovascular complications during L-asparaginase therapy.Klin. Padiatr.1994206433434110.1055/s‑2008‑10466267967435
     [Google Scholar]
  47. ScheuermannA. Harker-MurrayP. PommertL. Posterior reversible encephalopathy syndrome in the setting of asparaginase-associated pancreatitis in 2 pediatric patients with acute leukemia.J. Pediatr. Hematol. Oncol.2022443e709e71210.1097/MPH.000000000000236734966101
     [Google Scholar]
  48. EmrahE. GünE.G. Co-occurence of hypertension and seizures should prompt consideration of PRES and urgent neuroimaging, particularly in patients on immunosuppressants or chemotherapeutics. Hypertension should be addressed aggressively in patients with PRES Electroencepha.Clin. Neurol. Neurosurg.2022222107476
     [Google Scholar]
  49. Tortajada SolerJ.J. Tauler RedondoM.P. Garví LópezM. Lozano SerranoM.B. López-Torres LópezJ. Sánchez LópezM.L. Posterior reversible encephalopathy syndrome in critical COVID-19 patients: Report of 2 cases.Rev. Esp. Anestesiol. Reanim.2023701515510.1016/j.redar.2021.05.02234345055
     [Google Scholar]
  50. FugateJ.E. ClaassenD.O. CloftH.J. KallmesD.F. KozakO.S. RabinsteinA.A. Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings.Mayo Clin. Proc.201085542743210.4065/mcp.2009.059020435835
     [Google Scholar]
  51. MukherjeeP. McKinstryR.C. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging.Radiology2001219375676510.1148/radiology.219.3.r01jn4875611376265
     [Google Scholar]
  52. PanisB. VlaarA.M.M. van WellG.T.J. GranzenB. WeberJ.W. PostmaA.A. KlinkenbergS. Posterior reversible encephalopathy syndrome in paediatric leukaemia.Eur. J. Paediatr. Neurol.201014653954510.1016/j.ejpn.2010.01.00320171912
     [Google Scholar]
  53. AntunesN.L. Seizures in children with systemic cancer.Pediatr. Neurol.200328319019310.1016/S0887‑8994(02)00508‑812770671
     [Google Scholar]
  54. DarwishA.H. Posterior Reversible Encephalopathy Syndrome in Children: A Prospective Follow-up Study.J. Child Neurol.2020351556210.1177/088307381987647031570037
     [Google Scholar]
  55. AgarwalA. KapurG. AltinokD. Childhood posterior reversible encephalopathy syndrome: Magnetic resonance imaging findings with emphasis on increased leptomeningeal FLAIR signal.Neuroradiol. J.201528663864310.1177/197140091560933826515749
     [Google Scholar]
  56. AnastasopoulouS. Posterior reversible encephalopathy syndrome and other severe central nervous system adverse events in the nopho all2008 protocol: clinical and radiological findings, genetic risk factors, and prognosisKarolinska Institute2022
     [Google Scholar]
  57. BartynskiW.S. TanH.P. BoardmanJ.F. ShapiroR. MarshJ.W. Posterior reversible encephalopathy syndrome after solid organ transplantation.AJNR Am. J. Neuroradiol.200829592493010.3174/ajnr.A096018272559
     [Google Scholar]
  58. AnastasopoulouS. ErikssonM.A. HeymanM. WangC. NiinimäkiR. MikkelS. VaitkevičienėG.E. JohannsdottirI.M. MyrbergI.H. JonssonO.G. Als-NielsenB. SchmiegelowK. BanerjeeJ. Harila-SaariA. RantaS. Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Clinical characteristics, risk factors, course, and outcome of disease.Pediatr. Blood Cancer2019665e2759410.1002/pbc.2759430592147
     [Google Scholar]
  59. LegrielS. PicoF. AzoulayE. Understanding posterior reversible encephalopathy syndrome.In: Annual Update in Intensive Care and Emergency Medicine 2011. Annual Update in Intensive Care and Emergency MedicineSpringerBerlin, Heidelberg2011163165310.1007/978‑3‑642‑18081‑1_56
     [Google Scholar]
  60. SibaiB.M. Eclampsia.Am. J. Obstet. Gynecol.199016331049105410.1016/0002‑9378(90)91123‑T2403130
     [Google Scholar]
  61. FugateJ.E. RabinsteinA.A. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.Lancet Neurol.201514991492510.1016/S1474‑4422(15)00111‑826184985
     [Google Scholar]
  62. ParasoleR. PetruzzielloF. MennaG. MangioneA. CianciulliE. BuffardiS. MarcheseL. NastroA. MisuracaA. PoggiV. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.Leuk. Lymphoma20105161063107110.3109/1042819100375460820470218
     [Google Scholar]
  63. KadkolR. GodboleR.R. Antepartum eclampsia with posterior reversible encephalopathy syndrome.J. Obstet. Gynaecol. India201262S11272810.1007/s13224‑013‑0373‑724293865
     [Google Scholar]
  64. DicuonzoF. SalvatiA. PalmaM. LefonsV. LasalandraG. De LeonardisF. SantoroN. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings.J. Child Neurol.20092481013101810.1177/088307380933270519307676
     [Google Scholar]
  65. BakshiR. BatesV.E. MechtlerL.L. KinkelP.R. KinkelW.R. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings.Epilepsia199839329529910.1111/j.1528‑1157.1998.tb01376.x9578048
     [Google Scholar]
  66. GrahamB.R. PylypchukG.B. Posterior reversible encephalopathy syndrome in an adult patient undergoing peritoneal dialysis: A case report and literature review.BMC Nephrol.20141511010.1186/1471‑2369‑15‑1024411012
     [Google Scholar]
  67. ZekićT. BenićM.S. AntulovR. AntončićI. NovakS. The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients.Rheumatol. Int.201737122105211410.1007/s00296‑017‑3843‑x29043491
     [Google Scholar]
  68. VaraprasadI.R. AgrawalS. PrabuV.N.N. RajasekharL. KanikannanM.A. NarsimuluG. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus.J. Rheumatol.20113881607161110.3899/jrheum.10130821572160
     [Google Scholar]
  69. PavlidouE. PavlouE. AnastasiouA. PanaZ. TsotoulidouV. KinaliM. HatzipantelisE. Posterior reversible encephalopathy syndrome after intrathecal methotrexate infusion: A case report and literature update.Quant. Imaging Med. Surg.20166560561110.21037/qims.2016.10.0727942481
     [Google Scholar]
  70. PeddiP.F. PeddiS. SantosE.S. MorgenszternD. Central nervous system toxicities of chemotherapeutic agents.Expert Rev. Anticancer Ther.201414785786310.1586/14737140.2014.91108924745349
     [Google Scholar]
  71. HowJ. BlattnerM. FowlerS. Wang-GillamA. SchindlerS.E. Chemotherapy-associated posterior reversible encephalopathy syndrome.Neurologist201621611211710.1097/NRL.000000000000010527801773
     [Google Scholar]
  72. ArzanianM.T. ShamsianB.Sh. KarimzadehP. KajiyazdiM. MalekF. HammoudM. Posterior reversible encephalopathy syndrome in pediatric hematologic-oncologic disease: literature review and case presentation.Iran. J. Child. Neurol.20148211024949044
     [Google Scholar]
  73. IrvinW. MacDonaldG. SmithJ.K. KimW.Y. Dexamethasone-induced posterior reversible encephalopathy syndrome.J. Clin. Oncol.200725172484248610.1200/JCO.2007.10.999117557962
     [Google Scholar]
  74. FloeterA.E. PatelA. TranM. ChamberlainM.C. HendrieP.C. GopalA.K. CassadayR.D. Posterior reversible encephalopathy syndrome associated with dose-adjusted epoch (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) chemotherapy.Clin. Lymphoma Myeloma Leuk.201717422523010.1016/j.clml.2016.12.00428169156
     [Google Scholar]
  75. ZaccaraG. PeruccaE. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs.Epileptic Disord.201416440943110.1684/epd.2014.071425515681
     [Google Scholar]
  76. de LaatP. te WinkelM.L. DevosA.S. Catsman-BerrevoetsC.E. PietersR. van den Heuvel-EibrinkM.M. Posterior reversible encephalopathy syndrome in childhood cancer.Ann. Oncol.201122247247810.1093/annonc/mdq38220699277
     [Google Scholar]
  77. HincheyJ. ChavesC. AppignaniB. BreenJ. PaoL. WangA. PessinM.S. LamyC. MasJ.L. CaplanL.R. A reversible posterior leukoencephalopathy syndrome.N. Engl. J. Med.1996334849450010.1056/NEJM1996022233408038559202
     [Google Scholar]
  78. AmptoulachS. TsavarisN. Neurotoxicity caused by the treatment with platinum analogues.Chemother. Res. Pract.201120111510.1155/2011/84301922312559
     [Google Scholar]
  79. NormanJ.K. ParkeJ.T. WilsonD.A. McNall-KnappR.Y. Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia.Pediatr. Blood Cancer200749219820310.1002/pbc.2059716123992
     [Google Scholar]
  80. Sánchez-CarpinteroR. NarbonaJ. López de MesaR. ArbizuJ. SierrasesúmagaL. Transient posterior encephalopathy induced by chemotherapy in children.Pediatr. Neurol.200124214514810.1016/S0887‑8994(00)00242‑311275465
     [Google Scholar]
  81. KiermaszA. ZapałaM. ZwiernikB. Stręk-CholewińskaA. Machnikowska-SokołowskaM. Mizia-MalarzA. Posterior reversible encephalopathy syndrome in children with malignancies a single-center retrospective study.Front. Neurol.202314126107510.3389/fneur.2023.126107538020647
     [Google Scholar]
  82. OrtizA. ElsässerS. RoveranoS. PairaS. Síndrome de encefalopatía posterior reversible (PRES): comunicación de tres casos.Rev. Argent. Reumatol.20122335260
     [Google Scholar]
/content/journals/cds/10.2174/0115748863290290240710161133
Loading
Posterior Reversible Encephalopathy Syndrome Associated with L-Asparaginase Treatment in Children: Literature Review and Six Case Reports
Curr Drug Saf 20, 311 (2025); https://doi.org/10.2174/0115748863290290240710161133
/content/journals/cds/10.2174/0115748863290290240710161133
/content/journals/cds/10.2174/0115748863290290240710161133
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): acute lymphoblastic leukemia; blood-brain barrier; central nervous system; chemotherapy; L-asparaginase; leukoencephalopathy; posterior reversible encephalopathy syndrome; PRES

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test